Autolus Therapeutics plc

(NASDAQ:AUTL)

Latest On Autolus Therapeutics plc (AUTL):

Date/Time Type Description Signal Details
2023-05-07 15:51 ESTNewsAutolus Therapeutics plc 2023 Q1 - Results - Earnings Call PresentationN/A
2023-05-07 15:51 ESTNewsAutolus Therapeutics plc (AUTL) Q1 2023 Earnings Call TranscriptN/A
2023-05-04 08:04 ESTNewsAutolus Therapeutics GAAP EPS of -$0.23 beats by $0.04N/A
2023-03-14 15:28 ESTNewsAutolus Therapeutics finance chief steps downN/A
2023-03-07 14:48 ESTNewsAutolus Therapeutics GAAP EPS of -$1.57 beats by $0.06, revenue of $6.36M misses by $4.47MN/A
2023-03-07 14:48 ESTNewsAutolus Therapeutics (AUTL) Q4 2022 Earnings Call TranscriptN/A
2023-03-07 00:03 ESTNewsAutolus Therapeutics FY 2022 Earnings PreviewN/A
2023-02-15 06:45 ESTNewsAutolus: Investment Case Further Entrenched With Latest Interim FELIX DataN/A
2023-02-14 18:07 ESTNewsAutolus Therapeutics: The Story Has ImprovedN/A
2022-12-09 12:50 ESTNewsAutolus Therapeutics stock slide on pricing $150.0M ADS offeringN/A
2022-12-08 20:05 ESTNewsAutolus says mid-stage trial of CAR-T therapy for type of leukemia met main goalN/A
2022-12-08 20:05 ESTNewsAutolus Therapeutics to get $70M in milestone payments from Blackstone Life SciencesN/A
2022-12-08 20:05 ESTNewsAutolus Therapeutics stock tumbles ~20% after hours as co files for stock offeringN/A
2022-11-16 06:24 ESTNewsAutolus Therapeutics: Near-Term Catalyst Plus Several Bio Deals Could Shift MomentumN/A
2022-11-05 06:49 ESTNewsAutolus Therapeutics plc 2022 Q3 - Results - Earnings Call PresentationN/A
2022-11-05 06:49 ESTNewsAutolus Therapeutics plc (AUTL) Q3 2022 Earnings Call TranscriptN/A
2022-11-03 21:24 ESTNewsAutolus Therapeutics GAAP EPS of -$0.47 in-line, revenue of $2.37M beats by $2.23MN/A
2022-10-12 15:17 ESTNewsAutolus stock rises as Moderna uses option to license targeting technology for mRNA therapyN/A
2022-10-04 11:35 ESTNewsAutolus stock rises on Bristol Myers contract for use of safety switch with cell therapiesN/A
2022-08-17 12:30 ESTNewsAutolus Therapeutics: Overlooked CAR-T Player With Key Catalysts ApproachingN/A
2022-08-08 16:19 ESTNewsAutolus Therapeutics plc (AUTL) CEO Christian Itin on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-04 22:04 ESTNewsAutolus Therapeutics GAAP EPS of -$0.46 misses by $0.13N/A
2022-08-03 15:56 ESTNewsAutolus Therapeutics Q2 2022 Earnings PreviewN/A
2022-06-18 01:03 ESTNewsAutolus Therapeutics (AUTL) Investor Presentation - SlideshowN/A
2022-05-10 00:19 ESTNewsAutolus Therapeutics plc 2022 Q1 - Results - Earnings Call PresentationN/A
2022-05-08 08:57 ESTNewsAutolus Therapeutics plc (AUTL) CEO Christian Itin on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-05 18:49 ESTNewsAutolus Therapeutics GAAP EPS of -$0.41 beats by $0.07, revenue of $0.17M in-lineN/A
2022-05-04 19:58 ESTNewsAutolus Therapeutics Q1 2022 Earnings PreviewN/A
2022-04-25 16:05 ESTNewsAutolus stock rises 10% on FDA regenerative medicine status for obe-cel to treat blood cancer subtypeN/A
2022-04-14 17:48 ESTNewsAutolus Therapeutics (AUTL) Presents at the American Association for Cancer Research Annual Meeting 2022 - SlideshowN/A
2022-03-11 05:33 ESTNewsAutolus Therapeutics plc 2021 Q4 - Results - Earnings Call PresentationN/A
2022-03-11 05:33 ESTNewsAutolus Therapeutics plc (AUTL) CEO Dr. Christian Itin on Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-10 10:41 ESTNewsAutolus Therapeutics GAAP EPS of -$1.97 misses by $0.08, revenue of $2.33M misses by $4.87MN/A
2022-03-09 18:19 ESTNewsAutolus Therapeutics Q4 2021 Earnings PreviewN/A
2022-01-14 18:35 ESTNewsAutolus Therapeutics (AUTL) Developing Next Generation Programmed T Cell Therapies (Slideshow)N/A
2022-01-10 14:00 ESTNewsAutolus Therapeutics announces CFO retirement and succession planN/A
2021-12-16 00:39 ESTNewsAutolus Therapeutics (AUTL) Presents At 63rd Annual Meeting of ASH - SlideshowN/A
2021-11-09 01:43 ESTNewsAutolus Therapeutics surges on securing $250M strategic funding from BlackstoneN/A
2021-11-04 01:46 ESTNewsAutolus Therapeutics EPS beats by $0.04, misses on revenueN/A
2021-11-04 01:45 ESTNewsAutolus Therapeutics plc (AUTL) CEO Dr. Christian Itin on Q3 2021 Results - Earnings Call TranscriptN/A
2021-11-03 05:58 ESTNewsAutolus Therapeutics Q3 2021 Earnings PreviewN/A
2021-10-08 01:20 ESTNewsMNTV, AUTL, ALLO and CLLS among after hours moversN/A
2021-09-22 17:51 ESTNewsAutolus Therapeutics provides update on manufacturing facility in U.K.N/A
2021-08-07 12:39 ESTNewsAutolus Therapeutics plc (AUTL) CEO Christian Itin on Q2 2021 Results - Earnings Call TranscriptN/A
2021-08-06 17:03 ESTNewsAutolus Therapeutics plc 2021 Q2 - Results - Earnings Call PresentationN/A
2021-08-06 17:02 ESTNewsAutolus Therapeutics files $300M mixed shelf offeringN/A
2021-08-05 19:58 ESTNewsAutolus Therapeutics EPS beats by $0.04, beats on revenueN/A
2021-08-03 05:38 ESTNewsModerna gains access to Autolus' binder technology for mRNA immuno-oncology targetsN/A
2021-07-22 16:22 ESTNewsAutolus Therapeutics' obe-cel shows high clinical activity in blood cancers, shares rise 5%N/A
2021-07-22 16:17 ESTNewsAutolus: Developing Better CAR-T In Refractory ALLN/A

About Autolus Therapeutics plc (AUTL):

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 and AUTO8 for the treatment of multiple myeloma; AUTO1/22 for the treatment of dual-targeting CAR-T; AUTO3NG for the treatment of hematological cancer; AUTO4 and AUTO5 for T cell lymphoma; AUTO6NG for the treatment of programmed T cell therapies; AUTO6 for the treatment of neuroblastoma; and AUTO7 for the treatment of prostate cancer. Autolus Therapeutics plc was founded in 2014 and is headquartered in London, the United Kingdom.

AUTL Quotes by TradingView

See Advanced Chart

General

  • Name Autolus Therapeutics plc
  • Symbol AUTL
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 376
  • Fiscal Year EndSeptember
  • IPO Date2018-06-22
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.autolus.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 1470.04
  • Price/Book (Most Recent Quarter) 2.32
  • Enterprise Value Revenue 1600.67
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Next Quarter EPS Estimate -$0.78
  • Operating Margin -6571%
  • Return on Assets -22%
  • Return on Equity -30%
  • Revenue 1.08 million
  • Earnings Per Share -$1.40
  • Revenue Per Share $0.03
  • Gross Profit -133173000
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 483.68 million
  • EBITDA -68942608
  • Analyst Target Price $15.78
  • Book Value Per Share $5.91
View More

Share Statistics

  • Shares Outstanding 70.51 million
  • Shares Float 33.9 million
  • % Held by Insiders 3186%
  • % Held by Institutions 25.44%
  • Shares Short 3.51 million
  • Shares Short Prior Month 1.71 million
  • Short Ratio 2.67
  • Short % of Shares Outstanding 5%
View More

Technicals

  • Beta 1.75
  • 52 Week High $17.19
  • 52 Week Low $4
  • 50 Day Moving Average 7.05
  • 200 Day Moving Average 9.94
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Autolus Therapeutics plc (AUTL) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Autolus Therapeutics plc (AUTL) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-04$N/A-$0.83-$0.77-8.03%
2020-09-302020-11-05$N/A-$0.72-$0.71-1.84%
2020-06-302020-08-06$N/A-$0.62-$0.7011.29%
2020-03-312020-05-07$N/A-$0.60-$0.7519.57%
2019-12-312020-03-03$309000-$0.84-$0.74-14.27%
2019-09-302019-11-07$297000-$0.61-$0.8326.73%
2019-06-302019-08-08$338000-$0.65-$0.660.76%
2019-03-312019-05-14$1.96 million-$0.69-$0.56-22.49%
2018-12-312019-02-25$296000-$0.52-$0.6621.21%

Autolus Therapeutics plc (AUTL) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Autolus Therapeutics plc (AUTL) Chart:

Autolus Therapeutics plc (AUTL) News:

Below you will find a list of latest news for Autolus Therapeutics plc (AUTL) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Autolus Therapeutics plc (AUTL) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-06-200.50CALL0 10TRUE00
2025-06-2010CALL0 18221.73TRUE00
2025-06-201.50.3CALL0 291240.51TRUE00
2025-06-2020.09CALL0 38780.12FALSE00
2025-06-202.50CALL0 275115.5FALSE00
2025-06-2050CALL0 344250.88FALSE00
2025-06-207.50CALL0 51318.73FALSE00
2025-06-200.50PUT0 0370.35FALSE00
2025-06-2010PUT0 1183.48FALSE00
2025-06-201.50PUT0 170.99FALSE00
2025-06-2020PUT0 37210.44TRUE00
2025-06-202.50PUT0 890TRUE00
2025-06-2050PUT0 0391.1TRUE00
2025-06-207.50PUT0 0677.99TRUE00
2025-07-180.50CALL0 00TRUE00
2025-07-1810CALL0 0362.56TRUE00
2025-07-181.50.5CALL0 1165.68TRUE00
2025-07-1820.15CALL0 20233.37FALSE00
2025-07-182.50CALL0 090.83FALSE00
2025-07-1850.01CALL0 2161.57FALSE00
2025-07-187.50CALL0 0205.39FALSE00
2025-07-180.50PUT0 00FALSE00
2025-07-1810PUT0 0479.33FALSE00
2025-07-181.50PUT0 0251.78FALSE00
2025-07-1820PUT0 0137.35TRUE00
2025-07-182.50PUT0 096.91TRUE00
2025-07-1850PUT0 0231.17TRUE00
2025-07-187.50PUT0 0285.98TRUE00
2025-09-190.50CALL0 0183.38TRUE00
2025-09-1910CALL0 217190.56TRUE00
2025-09-191.50CALL0 499.59TRUE00
2025-09-1920.2CALL0 122152.31FALSE00
2025-09-192.50CALL0 165131.38FALSE00
2025-09-1950.1CALL1 15144.2FALSE0.10
2025-09-197.50CALL0 0152.5FALSE00
2025-09-190.50PUT0 00FALSE00
2025-09-1910PUT0 0317.57FALSE00
2025-09-191.50PUT0 0183.5FALSE00
2025-09-1920PUT0 3759.69TRUE00
2025-09-192.50.75PUT0 1167.44TRUE00
2025-09-1950PUT0 0175.97TRUE00
2025-09-197.50PUT0 0198.11TRUE00
2025-12-190.50CALL0 100TRUE00
2025-12-1910CALL0 23249.76TRUE00
2025-12-191.50.5CALL0 192130.27TRUE00
2025-12-1920.55CALL4 89121.77FALSE0.10.22
2025-12-192.50.25CALL0 88176.68FALSE00
2025-12-1950CALL0 627142.19FALSE00
2025-12-197.50CALL0 372168.72FALSE00
2025-12-190.50PUT0 1142.64FALSE00
2025-12-1910PUT0 0237.89FALSE00
2025-12-191.50.3PUT0 137108.39FALSE00
2025-12-1920.5PUT0 86109.91TRUE00
2025-12-192.50PUT0 12975.91TRUE00
2025-12-1950PUT0 15158.39TRUE00
2025-12-197.50PUT0 0230.96TRUE00

Latest AUTL Trades:

Date Shares Price
Jun 13, 2022 7:45 PM EST100$2.265
Jun 13, 2022 7:46 PM EST100$2.25
Jun 13, 2022 7:46 PM EST100$2.245
Jun 13, 2022 7:47 PM EST100$2.24
Jun 13, 2022 7:47 PM EST38$2.245

Autolus Therapeutics plc (AUTL) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-3020-F/AAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1730463/000119312520184031/0001193125-20-184031-index.htm
2019-07-22UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1730463/000000000019011382/0000000000-19-011382-index.htm
2020-06-18UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1730463/000000000020005460/0000000000-20-005460-index.htm
2020-07-09UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1730463/000000000020006207/0000000000-20-006207-index.htm
2019-02-13SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1730463/000119312519038198/0001193125-19-038198-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1730463/000119312519039614/0001193125-19-039614-index.htm
2019-02-256-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1730463/000119312519049964/0001193125-19-049964-index.htm
2019-03-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1730463/000119312519076928/0001193125-19-076928-index.htm
2019-03-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1730463/000119312519088447/0001193125-19-088447-index.htm
2019-04-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1730463/000119312519095146/0001193125-19-095146-index.htm
2019-04-056-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1730463/000119312519099275/0001193125-19-099275-index.htm
2019-04-08F-1Registration statement for certain foreign private issuershttps://www.sec.gov/Archives/edgar/data/1730463/000119312519100758/0001193125-19-100758-index.htm
2019-04-08CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1730463/000119312519100812/0001193125-19-100812-index.htm
2019-04-08CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1730463/000119312519100816/0001193125-19-100816-index.htm
2019-04-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1730463/000119312519100854/0001193125-19-100854-index.htm
2019-04-10F-1MEFRegistration statement to add securities to prior Form F-1 registration [Rule 462(b)]https://www.sec.gov/Archives/edgar/data/1730463/000119312519103095/0001193125-19-103095-index.htm
2019-04-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1730463/000119312519103379/0001193125-19-103379-index.htm
2019-04-11424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/1730463/000119312519103862/0001193125-19-103862-index.htm
2019-07-17F-3Registration statement by foreign private issuershttps://www.sec.gov/Archives/edgar/data/1730463/000119312519195733/0001193125-19-195733-index.htm
2019-07-22CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1730463/000119312519198985/0001193125-19-198985-index.htm
2019-07-24424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1730463/000119312519201243/0001193125-19-201243-index.htm
2020-01-22424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1730463/000119312520012120/0001193125-20-012120-index.htm
2020-01-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1730463/000119312520014188/0001193125-20-014188-index.htm
2020-01-24424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1730463/000119312520014199/0001193125-20-014199-index.htm
2020-01-316-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1730463/000119312520021437/0001193125-20-021437-index.htm
2020-02-11SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1730463/000119312520031373/0001193125-20-031373-index.htm
2020-05-266-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1730463/000119312520151568/0001193125-20-151568-index.htm
2020-06-226-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1730463/000119312520175566/0001193125-20-175566-index.htm
2020-06-3020-F/AAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1730463/000119312520184031/0001193125-20-184031-index.htm
2020-06-30CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1730463/000119312520184048/0001193125-20-184048-index.htm
2020-08-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1730463/000119312520231538/0001193125-20-231538-index.htm
2020-09-186-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1730463/000119312520248586/0001193125-20-248586-index.htm
2020-09-18424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1730463/000119312520248640/0001193125-20-248640-index.htm
2019-01-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1730463/000121390019000521/0001213900-19-000521-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1730463/000121390019002514/0001213900-19-002514-index.htm
2019-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1730463/000121390019002532/0001213900-19-002532-index.htm
2019-08-08SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1730463/000121390019014928/0001213900-19-014928-index.htm
2019-09-09SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1730463/000121390019017502/0001213900-19-017502-index.htm
2019-09-16SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1730463/000121390019018073/0001213900-19-018073-index.htm
2019-09-20SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1730463/000121390019018491/0001213900-19-018491-index.htm
2019-10-09SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1730463/000121390019020030/0001213900-19-020030-index.htm
2019-10-09SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1730463/000121390019020032/0001213900-19-020032-index.htm
2020-01-24SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1730463/000121390020001740/0001213900-20-001740-index.htm
2020-04-22SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1730463/000121390020009830/0001213900-20-009830-index.htm
2020-06-15SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1730463/000121390020015014/0001213900-20-015014-index.htm
2020-07-06SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1730463/000121390020016740/0001213900-20-016740-index.htm
2020-07-20SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1730463/000121390020017961/0001213900-20-017961-index.htm
2020-08-03SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1730463/000121390020019894/0001213900-20-019894-index.htm
2020-08-13SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1730463/000121390020021871/0001213900-20-021871-index.htm
2020-03-0320-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1730463/000162828020002797/0001628280-20-002797-index.htm
2019-02-2520-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1730463/000173046319000004/0001730463-19-000004-index.htm
2019-05-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1730463/000173046319000008/0001730463-19-000008-index.htm
2019-08-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1730463/000173046319000011/0001730463-19-000011-index.htm
2019-11-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1730463/000173046319000013/0001730463-19-000013-index.htm
2020-05-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1730463/000173046320000003/0001730463-20-000003-index.htm
2020-08-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1730463/000173046320000008/0001730463-20-000008-index.htm
2020-11-056-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1730463/000173046320000011/0001730463-20-000011-index.htm
2019-04-10EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1730463/999999999519000665/9999999995-19-000665-index.htm
2019-07-24EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1730463/999999999519001680/9999999995-19-001680-index.htm